Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Sandwich assay

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435700100 - Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

435700900 - Assay in which an enzyme present is a label

435700920 - Heterogeneous or solid phase assay system (e.g., ELISA, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045494METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Immumoglobulin A, Metalloproteinase inhibitor 4, and Thrombomodulin as diagnostic and prognostic biomarker assays in renal injuries.02-21-2013
20090215096Collodial silica particle containing light-absorbing susbstance, nano light-absorbing material,absorption labeling nanobead kit, and method for detection or quantification of biological molecule using the colloidal silica particle containing light-absorbing substance - A colloidal silica particle containing a light-absorbing substance, comprising a colloidal silica particle and a light-absorbing substance distributed over the colloidal silica particle, wherein the light-absorbing substance is chemically bound to or adsorbed on a silica component.08-27-2009
20120171705COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.07-05-2012
20080261253Methods and kits for the diagnosis of galactosemia - Provided are methods for the detection and diagnosis of galactosemia. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of galactosemia. At least two new biomarkers for galactosemia are thus disclosed, Eotaxin and MCP-1. Altogether the concentrations these markers, individually, or in combinations with any of Alpha-2 Macroglobulin, Apolipoprotein H, Cancer Antigen 125, Leptin, TNF RII, Alpha-Fetoprotein, IgM, MIP-1 alpha, Ferritin, and IgE provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from galactosemia. Kits containing reagents to assist in the analysis of fluid samples are also described.10-23-2008
20120183981METHOED FOR DETECTING CIRCULATING CARTILAGE OLIGOMERIC MATRIX PROTEIN IN THE DIAGNOSIS AND MONITORING OF CIRRHOSIS - The present invention is in the field of diagnostics, and in particular to the early diagnosis of liver cirrhosis in a patient not known to have liver cancer by detecting and measuring circulating cartilage oligomeric matrix protein (COMP) alone or in conjunction with one or more additional liver cirrhosis biomarkers in the biological fluid of a subject.07-19-2012
20120183980KIT FOR AMPLIFYING DETECTED SIGNAL IN IMMUNOSENSOR AND METHOD FOR DETECTING TARGET ANTIGEN USING THE SAME - Disclosed is a kit for amplifying detected signal in immunosensor and a method for detecting target antigen using the same according to the present invention, whereby a target antigen can be effectively detected even by a small amount of target antibody to thereby reduce nonspecific detection signal and to detect an amplified signal.07-19-2012
20100047832Assessment of Patients with Sepsis to Determine a Requirement for Therapeutic Intervention with an Anti-Inflammatory and/or Anticoagulatory Agent - Methods of selecting patients with sepsis for treatment with an anti-inflammatory and/or anticoagulatory agent are provided.02-25-2010
20130078656ARTIFICIAL IMMUNE SYSTEM: METHODS OF USE - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.03-28-2013
20130078655KIDNEY PROGNOSTIC ASSAY - The invention provides a method of predicting subjects at risk of loss of kidney function and/or identifying subjects at greater risk of loss of kidney function, and/or identifying subjects at risk of kidney failure/end stage kidney disease, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with increased risk of loss of kidney function and/or increased risk of renal failure/end stage kidney disease. A further aspect of the invention provides a method of monitoring renal impairment, comprising detecting an amount of free light chains (FLC) in a sample from a subject having renal impairment and comparing the amount of FLC in the sample with an Total FLC amount of FLC detected in a sample previously obtained from the subject, wherein an increase in the amount FLC detected, compared to the previous sample, indicates an increase in the risk of loss of renal function in the subject, and a decrease in the amount of FLC indicates a decrease in the risk of loss of renal function in the subject.03-28-2013
20130078657HYPERTHERMIA AUGMENTED IN-VITRO IMMUNE RECOGNITION - The present invention relates to a method for generation of a test-antigen specific cell-mediated immune response by incubating at hyperthermic conditions and, more particularly, a method for generation of a test-antigen specific cell-mediated immune response by incubating at hyperthermic conditions and optionally adding IL-7 and/or blocking IL-10. Even more particularly, the present invention provides a method for generating a cell-mediated response to an antigen using whole blood or other suitable bio-logical samples. The method is useful in for immune diagnosis of many infectious diseases, as a marker of immunocompetence, and for detection of T-cell responses to non-self antigens (i.e. infections and vaccines).03-28-2013
20120244562 METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS - Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals.09-27-2012
20130084587Levels of cytokeratins in blood and body fluids as biomarkers for cancer screening, diagnosis and treatment monitoring - Cytokeratins are intermediate filaments in the epithelial cells. Human cancers are malignant counterparts of normal epithelia. Human cancer cells express various kinds of cytokeratins dependent upon the specific cancer cell type. Pathologists have been using cytokeratin immunostaining for classification of tumor origins and cancer types. We claim that the protein levels of cytokeratin 7 (CK7) in the blood and/or body fluids are proportional to the tumor burden, and these protein levels of CK7 can be used as biomarkers for cancer screening, diagnosis and treatment monitoring.04-04-2013
20100129839Method for in vitro diagnosis of pvl-producing staphylococcus aureus - The present invention relates to a method for in vitro diagnosis of 05-27-2010
20130040325Enzyme Linked Immunosorbent Assay (ELISA) Method and Kit for Detecting Soluble Programmed Cell Death Protein 5 (PDCD5) - An enzyme linked immunosorbent assay (ELISA) method and kit for detecting soluble programmed cell death 5 (PDCD5) protein are provided. The method includes the following steps: (1) contacting a sample to be tested with a solid carrier loaded with a first antibody of PDCD5 protein; (2) adding a second antibody of PDCD5 protein, which is capable to binding to a detecting label; (3) adding the detecting label and detecting the bound detecting label. The soluble PDCD5 in a biological sample from a mammal comprising human can be detected by the ELISA method and kit. The method and kit can be used for detecting the level of PDCD5 protein in plasma, serum, urine, cerebrospinal fluid and synovial fluid so that an auxiliary detection method, for diagnosis of autoimmune disease, inflammation (such as hepatitis), and tumor etc., determination of disease course, observation of therapeutic effect and prognosis and medical guidance, is provided.02-14-2013
20130045495ELISA FOR VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.02-21-2013
20100105089QUANTUM DOT BIOTAGS - A biotag that includes a biomolecule that includes a bio polymer sequence; an attaching polymer attached at an endpoint of the biopolymer sequence; and a quantum dot bound to the attaching polymer causing the attaching polymer to become fluorescently labeled is provided. Suggested biomolecules include, but are not limited to, peptides, proteins, amino acids, nucleic acids, deoxyribonucleic acids, ribonucleic acids, and peptide nucleic acids. The biopolymer sequence may be or otherwise include a protein sequence. The biomolecule may be located inside a cell, outside a cell, or on a cell. Desirably, a quantum dot is bound to an attaching polymer and, thus the biomolecule, without using any of thiol chemistries, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide/N-hydroxysuccinimide hydrochloride (EDC/NHS) chemistries, and biotin/avidin chemistries. In certain desirable embodiments, the attaching polymer is attached at an endpoint of a biopolymer sequence using any of synthesizing, replicating, transcribing, translating, and expressing the attaching polymer at any of a C-terminal end or an N-terminal end of the biopolymer sequence.04-29-2010
20090136973DETERMINATION OF SHORT-CHAIN SRL ALCOHOL DEHYDROGENASE (DHRS4) AS A BIOMARKER FOR INFLAMMATIONS AND INFECTIONS - The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections.05-28-2009
20130029363METHOD FOR DIAGNOSING MALIGNANT TUMOR - To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence.01-31-2013
20100143953DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY BY MEANS OF NATRIURETIC PEPTIDES FOR NYHA I PATIENTS - The invention relates to a method for the diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency for NYHA I patients, wherein a determination of the proANP marker, NT-proANP marker, or fragments or partial peptides thereof is carried out parallel to a determination of BNP, proBNP, and/or NT-proBNP on patients to be examined.06-10-2010
20130052671IL-6 DETECTION BASED EARLY DIAGNOSIS AND PREDICTION OF SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME AND SEPSIS IN ASYMPTOMATIC PATIENTS - Methods, systems and kits for the early diagnosis or prediction of systemic inflammatory response syndrome (SIRS) including sepsis in asymptomatic patients, such as patients undergoing a surgical intervention, are provided. Some embodiments include a method and system for the detection or diagnosis of SIRS, or detection or diagnosis of a risk to suffer from or develop SIRS, in an asymptomatic patient comprising the steps of determining the level of IL-6 (or a variant thereof) in a sample from the patient; comparing the level of IL-6 (or a variant thereof) to a reference level; detecting or diagnosing SIRS or diagnosing a risk to suffer from or develop SIRS, wherein the sample is isolated at least 2 times at short intervals and the determining and comparing steps are both repeated for each sample. Also provided are methods, systems and kits for therapy monitoring and mortality prediction.02-28-2013
20130071865Devices And Methods For Detecting Amniotic Fluid In Vaginal Secretions - The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.03-21-2013
20120115175METHODS FOR DIAGNOSING ELEVATED RIGHT OR LEFT VENTRICULAR FILLING PRESSURE - The present invention features a method of diagnosing elevated left or right ventricular filling pressure and cardiovascular dysfunction in a subject by detecting increased levels of sEng in a biological sample from the subject.05-10-2012
20090029397Method for Monitoring Tocolytic Treatment - A method of monitoring tocolytic therapy in a pregnant woman. The method comprises determining a first concentration of placental protein 13 (PP13) in a bodily substance of a woman who has not received treatment with a tocolytic agent, determining a second concentration of PP13 in a bodily substance of the pregnant woman after initiation of treatment with a tocolytic agent, and comparing the second concentration with the first concentration. Based on the comparison, it may be determined whether to continue, discontinue, or modify the tocolytic treatment.01-29-2009
20090221009Diagnostic Method for Disorders Using Copeptin - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.09-03-2009
20090176259METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN - Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as botulinum neurotoxin, 07-09-2009
20130022998GLYCODELIN MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention.01-24-2013
20110076704Method for diagnosing alzheimer's disease using serum glycoprotein as biomarker - It is an object of the present invention to detect a change in the metabolism of a glycoprotein having an α2,6-sialyl residue, which is contained in blood, so as to provide an agent and a method for diagnosing sporadic Alzheimer's disease. The present invention provides an agent for diagnosing Alzheimer's disease, which comprises lectin used for detecting an α2,6-sialyl residue-containing glycoprotein.03-31-2011
20100221760METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING sAPPbeta - The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided.09-02-2010
20080311604Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of soluble VEGF-R2 as a biomarker for multi-kinase inhibitors.12-18-2008
20100035286IN VITRO METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS - In vitro method for the detection and early detection of, for the determination of the degree of severity of, and for the assessment of the course of and prognosis of neurodegenerative disorders, in which an immunodiagnostic determination method is used to determine the apolipoprotein C-1 (Apo C-1) immunoreactivity in a serum or plasma sample from a patient suffering from subjective or objectively verifiable cognitive disorders.02-11-2010
20100233741IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS - The present specification discloses SNAP-25 immune response inducing compositions, methods of making α-SNAP-25 antibodies that selectively binds to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P09-16-2010
20100267064METHODS FOR QUANTITATIVE TARGET DETECTION AND RELATED DEVICES AND SYSTEMS - Described herein is a method for detection of a target in a sample and related devices and systems.10-21-2010
20120034633MAGNETIC IMMUNOSENSOR AND METHOD OF USE - The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.02-09-2012
20090087869SANDWICH IMMUNOASSAY AND METHOD OF DETECTING AN ANTIGEN BY USING THE SAME - The invention provides a method of sandwich immunoassay comprising steps of, (a) forming a complex of an antigen and a first antibody by contacting the antigen with the first antibody which recognizes the antigen and which is labeled by a detectable labeling substance; and (b) fixing the complex formed in the step (a) to a solid phase by using a second antibody which recognizes the antigen and which is capable of binding to the solid phase, as well as a method for detecting an antigen in an analyte by using a method of sandwich immunoassay.04-02-2009
20090087868Neural Proteins as Biomarkers for Nervous System Injury and Other Neural Disorders - The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.04-02-2009
20090263840Novel Monoclonal Anitbody and Use thereof - The present invention provides an antibody capable of specifically recognizing the same amino acid sequence as an antigenic determinant of mouse monoclonal antibody MAB-ME-16F4.3 (FERM BP-10329), and an antibody of capable of specifically recognizing the same amino acid sequence as an antigenic determinant of mouse monoclonal antibody MAB-ME-12C9.2 (FERM BP-10328), and methods of risk prediction of bone fracture and/or diagnosis of osteoporosis by detecting a MEPE-derived molecule in a biological sample using the above-mentioned two kinds of antibodies.10-22-2009
20100124756COLLECTION OF BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ALZHEIMER'S DISEASE IN BODY FLUIDS - The inventors have discovered sets of proteinaceous biomarkers (“AD biomarkers”) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease. The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating the levels of the AD biomarkers.05-20-2010
20090291462Detection or Quantification of Aggrecan and its Fragments - An immunoassay for aggrecan and/or aggrecan derived fragments comprises contacting a sample with an immunological binding partner which has specific binding affinity for the G2 domain of aggrecan at least when bearing keratan sulphate chains, and determining the existence or amount of specific binding of the immunological binding partner, which may be conducted as a sandwich assay using a first antibody that binds an N-terminal amino acid sequence comprising FFGVG . . . and a second antibody that binds an N-terminal amino acid sequence comprising ARGS.11-26-2009
20120295289DEVICE AND METHOD FOR CULTURING CELLS - A device and method for culturing cells is described. Culture media is continuously or intermittently delivered to the cell culture for diluting concentration of at least one marker component in the cell culture. The concentration of the marker component may be measured continuously or intermittently to determined the culture media delivery rate.11-22-2012
20120295288SEROLOGICAL MARKER FOR DETECTING PANCREATIC CANCER AND A METHOD FOR USING THE SEROLOGICAL MARKER - UL16 binding protein 2 (ULBP2) is a protein overexpressed in pancreatic cancer tissues, and the ULBP2 levels are significantly higher in pancreatic cancer patients than those in healthy controls. This invention provides a method to detect pancreatic cancer using ULBP2 as a serological marker. The combination of ULBP2 and CA19-9 promotes the efficacy of pancreatic cancer detection. When measuring the blood ULBP2 levels in patients with other cancer types, including colorectal carcinoma, nasopharyngeal carcinoma and gastric cancer illustrates the blood ULBP2 levels are higher in patients with pancreatic cancer than other cancer types.11-22-2012
20120295290MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS - Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.11-22-2012
20080248510HUMAN Fc GAMMA RECEPTOR III - The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.10-09-2008
20080206797Csf Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases - CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.08-28-2008
20100093007Method of Diagnosis of Tuberculosis Related Immune Restoration Syndrome (IRS) - The present invention relates to a method and kit of diagnosis of Immune Restoration Syndrome associated with tuberculosis (TB-IRS) in patients infected with tuberculosis (TB) as well as in HIV co-infected patients comprising detecting an acute increase in Th1 response following exposure to mycobacterial extract, referred as tuberculin or PPD (Purified Protein Derivative) as well as to the 16 kDa protein, but not to ESAT-6 or CFP-10, two antigens from 04-15-2010
20090162878METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPB - The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided.06-25-2009
20130217049Methods and Systems for Signal Amplification of Bioassays - Disclosed herein are methods and systems for the detection of an analyte of interest by an amplified assay. The method and systems of the invention utilize the high specificity of biomolecules that have been coupled to a solid support to further amplify a signal produced by the interaction of a binding agent with the analyte of interest as a means to detect low levels of the analyte of interest present in a sample. In certain embodiments, for immunochemical (for example, ELISA or RIA) or immunofluorescence assays in which a protein to be identified is bound directly or through capture antibodies to a passivated surface, amplification of ˜10,000-fold can be achieved.08-22-2013
20130217050METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING-SOLUBLE GPVI - Provided are an agent for noninvasively and easily diagnosing Alzheimer's disease, a method for diagnosing Alzheimer's disease through the measurement, and a measurement kit therefor. The present invention relates to a reagent for measuring soluble GPVI (sGPVI) in a human body fluid; an agent for specifically diagnosing Alzheimer's disease, said agent comprising a reagent for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid; and a method for specifically diagnosing Alzheimer's disease, said method comprising a step for measuring the concentration of sGPVI in a collected human body fluid and a step for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid.08-22-2013
20110143382IgA Nephropathy Testing Method And Test Kit - There is provided a renal disease testing method comprising a complex detection step of detecting a complex of an antigen derived from human renal mesangial cells and human IgA in a sample derived from urine collected from a subject. It is preferred that the renal disease testing method of the invention further comprises a determination step of assessing the whether the renal disease is IgA nephropathy based on the ratio of the amount of the complex detected in the complex detection step to the amount of urinary proteins in the sample. The renal disease testing method of the invention has good detection sensitivity and specificity, and can conveniently and safely assess the existence of a renal disease (preferably, IgA nephropathy).06-16-2011
20090117597Method for Measuring Heptoglobin Level in Blood Serum and Kit Therefor - The present invention relates to a method for measuring heptoglobin level in blood serum by using antibodies for α and β subunits of heptoglobin, and a kit for immunodetection of heptoglobin which comprises the antibodies for α and β subunits of heptoglobin for measuring heptoglobin level in blood serum. A method for measuring heptoglobin level in blood serum of the present invention comprises the steps of: reacting blood serum of a subject with an antibody (αh antibody) which binds specifically to α subunit of a dimeric heptoglobin and an antibody (βh antibody) which binds specifically to β subunit of a dimeric heptoglobin; and, measuring level of proteins which react with the αh antibody and βh antibody in blood serum and have a molecular weight of more than 100 kDa. The method for measuring heptoglobin level in blood serum can be practically applied for the early diagnosis of diseases which disrupt erythrocytes, since only the level of normal heptoglobin except for monomelic and degraded hep-toglobins can be specifically measured by the said method.05-07-2009
20130137124DIAGNOSTIC TEST TO EXCLUDE SIGNIFICANT RENAL INJURY - Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associate lipocalin (NGAL) are provided.05-30-2013
20130122530PREDICTION AND RECOGNITION OF ACUTE KIDNEY INJURY AFTER SURGERY - Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.05-16-2013
20100227343GLYCODELIN MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF OVARIAN CANCER - Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention.09-09-2010
20100240078METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES - The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant.09-23-2010
20100221761MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.09-02-2010
20100009394UNIVERSAL TANDEM SOLID-PHASES BASED IMMUNOASSAY - Universal tandem solid-phases based immunoassay (UTSIA) is a sandwich-ELISA equivalent assay for low abundance antigen determination that overcomes limitations of sandwich-ELISA (antibody inactivation by solid phase and strict requirement of a pair of primary and secondary antibodies) by using an affinity binding solid phase to capture antigen specifically from a fluid sample, sequentially dissociating the antigen, transferring, and coating the antigen to a non-affinity binding solid phase for specific antigen determination. Cell-based UTSIA is a cell-based ELISA equivalent assay that overcomes limitations of image method for determining an antigen in the cells or tissue immobilized on a solid phase by dissociating and transferring the detection antibody bound on the antigen of the cells or tissue immobilized on the solid phase to a second solid phase and immobilizing the detection antibody there for specific detection of the antigen via the detection of the detection antibody.01-14-2010
20100304413DIAGNOSTIC USE OF INDIVIDUAL MOLECULAR FORMS OF A BIOMARKER - Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.12-02-2010
20110039284METHODS OF PROGNOSIS - The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample such as serum.02-17-2011
20110039283DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1 - The invention relates to a method for the diagnosis and/or risk stratification of cardiac diseases and diseases of the respiratory tract and lungs. According to said method, the free fragment N-terminal proEndothelin (NT-proET-1; AS 18-52 of the pre-proET according to FIG. 02-17-2011
20090142783Human p51 Genes and Gene Products Thereof - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1.06-04-2009
20110129861MEASUREMENT OF ANTI-CCP AND SERUM AMYLOID A METHOD TO ASSESS RHEUMATOID ARTHRITIS - The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.06-02-2011
20110244495METHOD FOR TESTING ALZHEIMER'S DISEASE BY MEASURING DEGRADATION RATE OF -AMYLOID IN BLOOD AND DIAGNOSTIC REAGENT - Provided is a method of testing Alzheimer's disease using serum or plasma as a sample. It is found that a β-amyloid peptide added to a blood sample is degraded. The degradation activity thereof was compared between the blood samples of normal subjects and Alzheimer's disease patients, and it is also found that the degradation activity is significantly higher in the blood of the normal subjects.10-06-2011
20090311728Novel Platelet Activation Marker and Method for Determination Thereof - The present invention provides a convenient and highly sensitive method of determining sGPVI present in plasma; this is accomplished by establishing a plurality of mouse hybridomas that produce antibody against GPVI and combining the antibodies produced therefrom. Provided thereby are a novel platelet activation marker, a reagent and method for determining this novel platelet activation marker, and novel applications of this marker in, for example, the diagnosis of diseases associated with platelet activation/vascular endothelial injury.12-17-2009
20100221759ASSAY FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE RATIO OF GAMMA-SECRETASE ABETA CLEAVAGE PRODUCTS - Described is a method for the diagnosis of Alzheimer's disease (AD) or a particular stage of the disease which is based on the determination of the ratio of at least two gamma-secretase cleavage products, Abeta48, Abeta45, Abeta42, Abeta38 and Abeta35, preferably the ratio of Abeta38: Abeta42. A decreased ratio of Abeta38: Abeta42 as compared to the normal ratio is indicative of AD. Moreover, kits suitable for carrying out said diagnostic method are described.09-02-2010
20120244563METHOD OF DETECTING PANCREATIC CANCER - To provide a method of accurately detecting pathological haptoglobin using a lectin having strong affinity and high specificity for fucose. The method of the present invention for detecting pancreatic cancer is characterized in that a fucose α1→6 specific lectin is allowed to act on pathological haptoglobin contained in a sample obtained from a living body, said lectin: (1) being extractede from basidiomycetes, (2) having a molecular weight of 4,000 to 40,000 as determined by the SDS polyacrylamide gel electrophoresis, and (3) having affinity for a fucose α1→6 sugar chain with a binding constant of 1.0×1009-27-2012
20110177538BIOMARKERS FOR RHEUMATOID ARTHRITIS (RA) - The invention provides methods for predicting and compositions for use in the prediction of rheumatoid arthritis (RA) based upon the simultaneous measurement of at least two biomarkers in a biological sample. The invention further relates to methods for following the efficiency of a treatment against RA and to methods for identifying test substances that are likely to prevent or diminish RA.07-21-2011
20100068738Method of Immunoassaying A Component to be Measured - A method of immunoassaying a component to be measured in a sample containing hemoglobin, which comprises reacting a component to be measured in a sample containing hemoglobin with an antibody capable of binding to the component in the presence of a bile acid derivative different from a bile acid derivative that is inherently contained in the sample; a method of suppressing an interference of hemoglobin in immunoassaying a component to be measured in a sample containing hemoglobin, which comprises reacting a component to be measured in a sample containing hemoglobin with an antibody capable of binding to the component in the presence of a bile acid derivative different from a bile acid derivative that is inherently contained in the sample; a reagent of immunoassay of a component to be measured in a sample containing hemoglobin, which comprises a bile acid derivative, are described.03-18-2010
20110076705COMPOSITIONS AND METHODS FOR EARLY PREGNANCY DIAGNOSIS - Disclosed are antibodies and methods for detecting pregnancy in an animal. In certain aspects antibodies used binds immunologically to at least two PAGs selected from PAG4, PAG6, PAG9, PAG16, PAG17, PAG19, PAG20 and PAG21. Antibody encoding nucleic acids are also provided, as are kits, methods of use and additional antibody related compositions.03-31-2011
20120149044INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY - The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.06-14-2012
20120149043URINARY BIOMARKERS FOR CANCER DIAGNOSIS - The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.06-14-2012
20120149042METHODS FOR PREDICTING OUTCOME IN TRAUMATIC BRAIN INJURY - The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.06-14-2012
20090317845Impulsive Noise Sensor - The present invention provides a method for measuring the presence of an analyte in a sample, wherein the presence of the analyte is indicated by the presence or absence of one or more trigger elements that generate an impulsive noise when triggered, comprising the steps of: (a) exposing the one or more trigger elements to a triggering impulse; and (b) detecting the impulsive noise generated by said one or more trigger elements. The present invention further provides reagents that can be used in the method of the present invention.12-24-2009
20090221010Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.09-03-2009
20090029396Assay kit and antibody for human low molecular weight CD14 - The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.01-29-2009
20110256563METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.10-20-2011
20110256562METHODS FOR DIAGNOSING HEART FAILURE AND OTHER CARDIAC DISEASES - The invention relates to methods of diagnosing the severity of heart failure or a cardiac dysfunction in a subject. The invention further relates to monitoring the severity of heart failure in a subject and determining the prognosis of a subject that has suffered from heart failure. This invention also relates methods to identify patients at risk for cardiac dysfunction when exposed to cardiotoxic chemotherapy agents.10-20-2011
20120202231SYNERGISTIC BIOMARKER ASSAY OF NEUROLOGICAL CONDITION USING S-100B - Processes and assays are provided for detecting and determining the magnitude of traumatic brain injury such as that from impact or percussive trauma or stroke. The inventive assays and processes recognize a synergistic correlation between detection of S-IOOb and one or more other injury specific biomarkers.08-09-2012
20110117585Quantitative multiplex detection of pathogen biomarkers - The present invention addresses the simultaneous detection and quantitative measurement of multiple biomolecules, e.g., pathogen biomarkers through either a sandwich assay approach or a lipid insertion approach. The invention can further employ a multichannel, structure with multi-sensor elements per channel.05-19-2011
20100159492Method for the Diagnosis of Diseases by Determining Apolipoprotein C-1 - A method for the diagnosis, early detection, risk estimation and control of the course of diseases, wherein the amount of apolipoprotein C-I and/or derivatives thereof is determined in a serum or plasma sample from a human patient and it is possible to conclude as to the presence of a disease, particular a tumoral disease or sepsis, on the basis of a result deviating significantly from the value range determined for normal healthy persons. The invention also relates to the use of apolipoprotein C-I in the therapy and prevention of diseases wherein the amount of or binding ability of apolipoprotein C-I in the blood of sick persons is significantly different from that of normal persons.06-24-2010
20100196937CASCADE ENZYME-LINKED IMMUNOSORBENT ASSAY - The present invention relates to a cascade enzyme-linked immunosorbent assay, more precisely a cascade enzyme-linked immunosorbent assay using magnetic microparticles (MMPs) immobilized with the target antigen specific primary antibody and silica nanoparticles (SPs) immobilized with a cascade reaction initiator and the antigen-specific secondary antibody. When the method of the present invention is applied in the detection of an antigen in biosamples, the detection sensitivity can be significantly increased.08-05-2010
20100196938IMMUNOASSAY FOR VENOM DETECTION INCLUDING NONINVASIVE SAMPLE COLLECTION - Methods and immunoassays for diagnosing a bite or sting of a venomous organism in a patient having symptoms consistent with such a bite or sting are provided. A sample of venom is collected from the area of the suspected bite or sting using a swab and then contacted with an antibody that specifically binds to an antigenic site on venom present in the sample. Binding is then detected. The invention is illustrated by examples showing diagnosis of brown recluse spider bite, distinguishing it from other diagnoses with which it is often confused. This extremely sensitive test can detect venom antigens down to about 20 picograms even after the sample has been shipped and stored for periods of up to three weeks during the summer.08-05-2010
20100062463IN VITRO MULTIPARAMETER DETERMINATION METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS - In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.03-11-2010
20100143954Galectin-3 Immunoassay - The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.06-10-2010
20090123952Method of Measuring Amyloid-Beta Peptides - The present invention relates to methods for measuring Aβ peptides in a sample, particularly a sample of blood, such as whole blood and plasma, and to methods of determining whether a compound alters the amount of Aβ produced by a cell or animal.05-14-2009
20120040381PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.02-16-2012
20120040380OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE - The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a β-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a β-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a β-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a β-lactmase or instructions for using the components in an assay.02-16-2012
20090311729DIAGNOSIS OF ACUTE ENTEROCOLITIS BY DETERMINATION OF INTESTINAL FATTY ACID-BINDING PROTEIN IN THE BLOOD - The present invention provides a quick and convenient determination method and a determination reagent for acute enterocolitis, which can determine acute enterocolitis quantitatively and objectively.12-17-2009
20120301906TSH IMMUNOASSAYS EMPLOYING SCAVENGING REAGENTS FOR CROSS-REACTING ENDOCRINE GLYCOPROTEIN HORMONE ANALOGUES - The invention relates to Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogues such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).11-29-2012
20120301905TSH IMMUNOASSAYS AND PROCESSES FOR PERFORMING TSH IMMUNOASSAYS IN THE PRESENCE OF ENDOGENOUS CONTAMINANTS IN RESTRICTED WASH FORMATS - The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).11-29-2012
20110014639HYBRIDOMA CELL LINE PRODUCING MONOCLONAL ANTIBODY AGAINST FOOT-AND-MOUTH DISEASE VIRUS, THE MONOCLONAL ANTIBODY THEREFROM, IMMUNOASSAY REAGENT AND KIT, AND IMMUNOASSAY METHOD - Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.01-20-2011
20080280311Immunoassay for the Simultaneous Immunochemical Determination of an Analyte (Antigen) and a Treatment Antibody Targeting the Analyte in Samples (Recovery Immunoassay) - The invention relates to an immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay). The inventive immunoassay comprises an optionally marked catcher antibody bound to a surface, a marked treatment antibody, or a marked antibody which has the same binding epitope as the treatment body, an antigen that binds to the catcher antibody and the treatment antibody in the region of various epitopes, and in this way forms an immunochemical sandwich, a solution of the unmarked treatment antibody of a known concentration, and an antigen solution to be added to the samples. The invention can be applied to the fields of medical diagnosis, treatment control and pharmacological research.11-13-2008
20120045783Method of determining tropomyosin in chitosan - A method capable of easily determining with high accuracy a protein in chitosan, the protein having a potential relevance to the development of an allergy, specifically tropomyosin and the content of the peptide. According to the method, tropomyosin is determined by immunoassay with the chitosan being in a state dissolved in an aqueous solution of an organic acid. The method also provides chitosan, which has a measurement value of the protein, specifically tropomyosin, not higher than a predetermined value as measured by the determination method and is assessed to have only a low risk of inducing the allergy.02-23-2012
20120208217METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.08-16-2012
20120208218METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.08-16-2012
20120009609DEVICES AND METHODS FOR DETECTING AMNIOTIC FLUID IN VAGINAL SECRETIONS - The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.01-12-2012
20120009610ENDOSTATIN AS A MARKER OF HEART FAILURE - Disclosed is a method for assessing heart failure in an individual including the steps of a) measuring in a sample obtained from the individual the concentration of the marker endostatin, of b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. Also disclosed are the use of endostatin as a marker protein in the assessment of heart failure, a marker combination comprising endostatin, and a kit for measuring endostatin.01-12-2012
20120015387MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT - An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa.01-19-2012
20110091915IgA Nephropathy Testing Method and Test Kit - There is provided a renal disease testing method comprising a complex detection step of detecting a complex of human uromodulin and human IgA in a sample derived from urine collected from a subject. It is preferred that the renal disease testing method of the invention further comprises a determination step of assessing the whether the renal disease is IgA nephropathy based on the ratio of the amount of the complex detected in the complex detection step to the amount of urinary proteins in the sample. The renal disease testing method of the invention has good detection sensitivity and specificity, and can conveniently and safely assess the existence of a renal disease (preferably, IgA nephropathy).04-21-2011
20110091914Immunological Test Element with Improved Control Zone - The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g., an enzyme, fluorescent or direct label, etc.) wherein the conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e., which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte.04-21-2011
20110104726Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.05-05-2011
20120122128IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P05-17-2012
20120122129RAPID NASAL ASSAY KIT - The present invention relates to an assay which can be used on nasal secretions. The assay is used to determine the cause of nasal secretions, for example whether the secretions are due to an allergic reaction or a non-allergic reaction.05-17-2012
20100248273AMELIORATION OF HETEROPHILE ANTIBODY IMMUNOSENSOR INTERFERENCE - The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 μg/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.09-30-2010
20100248274ANTIBODY DIRECTED AGAINST PRO-GASTRIN RELEASING PEPTIDE, AND USE THEREOF - Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.09-30-2010
20100248275METHODS FOR PREDICTING OUTCOME IN TRAUMATIC BRAIN INJURY - The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.09-30-2010
20120315655BIOMARKERS OF MUSCULOSKELETAL DISEASE - The present invention relates, in general, to biomarkers of musculoskeletal disease and, in particular, to methods of as diagnosing musculoskeletal disease, and/or predicting disease progression, by assaying for such biomarkers. The invention further relates to compounds and compositions suitable for use in such methods.12-13-2012
20120164669MARKER PANEL FOR LEFT VENTRICULAR HYPERTROPHY - The present disclosure relates to methods, compositions, kits and devices for diagnosing, distinguishing and/or facilitating a therapeutic decision in a subject having left ventricular hypertrophy. In some aspects, the methods, compositions, kits and devices disclosed herein allow for diagnosing, distinguishing and/or facilitating a therapeutic decision in a subject having physiological left ventricular hypertrophy, and/or for a subject suffering from pathological left ventricular hypertrophy.06-28-2012
20120171704Elisa for a naturally-occurring soluble truncated form of IL-23 receptor - A naturally-occurring soluble truncated IL-23Rα protein (i.e., Δ9 IL-23Rα) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23Rα protein. More particularly, antibody-sandwich ELISA method and kits for Δ9 IL-23Rα as an antigen were developed to detect Δ9 IL-23Rα levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.07-05-2012
20120214185METHOD OF SCREENING MHC MOLECULES - The invention relates to a method for screening the binding properties of constituent peptides of MHC molecules by providing in solution MHC molecules or their constituent peptides for a set of MHC molecules including a plurality of subsets of MHC molecules, wherein the MHC molecules of each subset differ from MHC molecules of at least one other subset in at least one of the putative MHC binding peptide, an MHC alpha chain and an MHC beta chain, and loading said MHC molecules with an MHC binding peptide by (i) refolding of the MHC alpha chain and beta chain peptides in presence of said MHC binding peptide or (ii) by peptide exchange or loading with an unlabelled MHC binding peptide in the absence of any labelled MHC binding peptide, (b) taking of at least one sample from each subset, and (c) determining loading efficiency for the sample of step (b).08-23-2012
20120214186METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING sAPPbeta - The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided.08-23-2012
20120077212METHODS OF DIAGNOSING ALS - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.03-29-2012
20120315656HYPERGLYCOSYLATED HCG DETECTION DEVICE - The present invention related to a pregnancy test device that can selectively detect hyperglycosylated human chorionic gonadotropin (hCG-H) in a liquid sample. The sample can be deposited on a proximal portion of the device for transport to a distal portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a capture site, in fluid communication with the release medium and formed of a second, different material. At least one of the release medium and the capture medium includes a binding member that exhibits a moderate to high affinity for hCG-H and is selectively or preferentially reactive with hCG-H.12-13-2012
20120178112METHOD OF DETECTING SKELETAL MUSCLE DAMAGE - The present invention relates to a method of detecting skeletal muscle damage and to the use of certain proteins and fragments thereof as biological markers (commonly known as “biomarkers”) for such damage. The present invention has particular reference to the detection of muscle toxicity in mammals, particularly humans.07-12-2012
20090061467Methods and Compositions for Measuring Canine BNP and Uses Thereof - The present invention describes compositions and methods designed to determine the presence or amount of BNP or fragments thereof in a sample. In particular, the invention provides materials that may be configured to bind canine BNP in a sandwich assay format. The present invention provides, inter alia, assays designed to rapidly and accurately measure BNP-related species in non-human animals.03-05-2009
20120264149METHOD FOR THE DETERMINATION OF THE FORMATION OF ENDOTHELINS FOR MEDICAL DIAGNOSTIC PURPOSES, AND ANTIBODIES AND KITS FOR CARRYING OUT SUCH A METHOD - An in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient for medical diagnostics purposes, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin, in particular a C-terminal peptide fragment.10-18-2012
20120190051METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.07-26-2012
20120329080ANTI-HLA ASSAY AND METHODS - Anti-MHC assay methodologies utilize functionally active, recombinantly produced, truncated individual soluble MHC trimolecular complexes that are linked to a substrate.12-27-2012
20120329079Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk - A method for assessing risk of prostate cancer utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination is provided. Also provided is a method for assessing risk of cancer utilizing Pro108 or specific antibodies to Pro108. Antibodies that bind to Pro108 on a mammalian cell in vivo and compositions comprising an anti-Pro108 antibody and a carrier which can be provided in an article of manufacture or a kit are also provided. An isolated nucleic acid encoding an anti-Pro108 antibody, an expression vector comprising the isolated nucleic acid, cells that produce the anti-Pro108 antibodies and a method of producing the anti-Pro108 antibodies as well as methods for use of the antibodies in killing an Pro108-expressing cancer cell and alleviating or treating an Pro108-expressing cancer in a mammal are also provided.12-27-2012
20090017480BIOAMPLIFICATION FOR MICROBIAL SENSOR SIGNAL TRANSDUCTION - A process of detection of the causative agent of Johne's disease (01-15-2009
20120322090SOLID PHASE-BOUND ELASTASE-BINDING ASSAY FOR THE MEASUREMENT OF ALPHA1-ANTITRYPSIN ACTIVITY - The present invention relates to a method for the measurement of active alpha12-20-2012
20120270246PROCOLLAGEN C-PROTEINASE ENHANCER (PCPE) BIOMARKER FOR BONE FORMATION - A method of diagnosing fibrosis in a subject is provided, comprising the steps of: determining a level of PCPE in a body fluid sample obtained from said subject; and detecting an increased level of PCPE in said body fluid sample relative to a normal control level of PCPE, wherein said increased level of PCPE relative to normal control is indicative of fibrosis in said subject. Furthermore, methods for evaluating the pharmacological efficacy of a drug or a drug candidate in treatment of fibrosis in a patient and for monitoring change of fibrosis in a subject are provided.10-25-2012
20100203560IMMUNOASSAY FOR QUANTIFICATION OF AN UNSTABLE ANTIGEN SELECTED FROM BNP AND proBNP - The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.08-12-2010
201202765625.9 kDa PEPTIDE IMMUNOASSAY METHOD - Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the α-E chain and α chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.11-01-2012
20110262941PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.10-27-2011
20110262940CAPILLARY FOR IMMUNOASSAY, AND CAPILLARY IMMUNOASSAY METHOD USING SAME - A capillary for an immunoassay is provided which comprises an insoluble layer of an oxidase formed on an inner wall surface of said capillary, said oxidase being conjugated to a first antibody, and a layer of a hydrophilic polymer formed on said insoluble layer, said hydrophilic polymer layer containing a second antibody conjugated to a peroxidase, wherein said first and second antibodies are capable of binding to the same antigen.10-27-2011
20110306071Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase - The invention provides assays and methods for determining the substrate specificity of gamma secretase inhibitors and for identifying substrate-selective (and substrate isoform-selective) inhibitors of gamma secretase. The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a site specific or substrate specific manner. The invention provides isolated polypeptide sequences comprising modified gamma secretase substrates, and polynucleotide sequences encoding the polypeptide sequences. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds.12-15-2011
20100167324Quantitative Assays for Ras p21 in Body Fluids - The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy.07-01-2010
20080248509METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE WITH DETERMINATION OF LASP-1 IMMUNOREACTIVITY - Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.10-09-2008
20130171672Methods for Detecting Oncofetal Fibronectin - Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronectin for selection of concepti are07-04-2013
20130171673PIPETTE TIP, PIPETTE SYSTEM AND METHOD FOR PERFORMING ANALYSIS WITH THE PIPETTE TIP AND SYSTEM - The present invention relates to a pipette tip (07-04-2013
20090280513COMPOSITIONS AND METHODS FOR DETECTION, PREVENTION, AND TREATMENT OF ANTHRAX AND OTHER INFECTIOUS DISEASES - Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods of immunizing humans or animals against 11-12-2009
20130095508INSTRUMENTED PIPETTE - A pipette component for use in performing an experimental procedure with a fluid sample and a pipette, the pipette component including: a pipette interface configured to engage sealingly and separably with a body of the pipette; a tip interface configured to engage sealingly and separably with a replaceable tip; and an experiment region configured to receive at least part of the fluid sample by operation of the pipette, and configured to perform at least part of the experimental procedure in the experiment region using the at least part of the fluid sample.04-18-2013
20130115640ACTH for Treatment of Kidney Disease - Provided herein are methods for prophylactic treatment of Diabetes Mellitus comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing Diabetes Mellitus. Also provided herein are methods for monitoring treatment of Diabetes Mellitus by measuring and monitoring levels of MCP-1, TGF-β, VEGF A and VEGF B.05-09-2013
20130115639METHOD FOR DETECTING A SALMONELLA INFECTION - The invention relates to a diagnostic method to detect a salmonellae infection and/or salmonellae contamination. Fields of use include medicine, veterinary medicine and various branches of industry.05-09-2013
20130130288Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers - This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.05-23-2013
20130143245RECOMBINANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERIVED FROM HUMAN MYOCARDIUM - Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.06-06-2013
20080199892Process for Screening Glycoform-Specific Antibodies - The present invention relates to the use of the assessment of the binding between—antibodies elicited against a first glycoprotein, and—at least one glycoform of a second glycoprotein, said second glycoprotein being itself a glycoform of the first protein, wherein said glycoform of the second glycoprotein is selected from a group of glycoforms of the second glycoprotein, each glycoform of said group corresponding to a determined glycosylation state defined by a determined sialylation state, and/or a determined branching state, and/or a determined fucosylation state, provided that said glycosylation state is not uniquely defined by a substantially unsialylated state, for the screening of glycoform specific antibodies directed against a given glycoform of the second glycoprotein.08-21-2008
20130149726POTENCY TEST FOR VACCINE FORMULATIONS - The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.06-13-2013
20130157296RECOMBINANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERVIVED FROM HUMAN MYOCARDIUM - Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.06-20-2013
20130157297METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha-2-HS-glycoprotein, Interleukin-9, Leukemia inhibitory factor, Macrophage colony-stimulating factor 1, Prolactin, and Stromal cell-derived factor 12 as diagnostic and prognostic biomarkers in renal injuries.06-20-2013
20130183698IMMUNOCHROMATOGRAPHY DEVICES, METHODS AND KITS - A membrane-based assay device, methods and kits for determining the presence or quantity of an analyte in a test sample are provided. The immunochromatographic device comprises a membrane having a capture antibody bound thereto at a test zone, wherein the capture antibody is capable of binding with an analyte, in particular a Z-AAT protein present in a sample from a PiZ gene carrier.07-18-2013
20110287458METHOD AND COMPOSITION FOR THE DIAGNOSIS AND MONITORING OF INFLAMMATORY DISEASES - The present invention provides a canine S100 calcium binding protein useful in diagnosing an inflammatory disease. Also provided are methods of diagnosing an inflammatory disease by assaying a biological sample for the canine S100 calcium binding protein. The invention further provides antibodies specifically binding to the canine S100 calcium binding protein and related kits comprising the antibodies.11-24-2011
20110294148TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER - The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.12-01-2011
20110312000MONOCLONAL ANTIBODY AND USE THEREOF - The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.12-22-2011
20120021444METHOD FOR DIAGNOSIS OF CYSTIC FIBROSIS USING KL-6 LEVELS - The present invention provides a method for diagnosis of cystic fibrosis, the method comprising: measuring an amount of KL-6 in a sample of body fluid from a subject, and determining, based on the amount of KL-6 measured, the degree of presence of cystic fibrosis in the subject.01-26-2012
20120028281INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY - The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF.02-02-2012
20130210041METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.08-15-2013
20130210042DIAGNOSTIC AND PROGNOSTIC METHOD FOR HUMAN TAUOPATHIES - The present invention relates to a method for the diagnosis and/or prognosis of tauopathies, in particular Alzeimer's disease. The method is based on the detection and quantification of a 20-22 kDa NH2-tau fragment.08-15-2013
20130210043METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.08-15-2013

Patent applications in class Sandwich assay